## Contents

**JUNE 2014**  
**VOLUME 4**  
**NUMBER 6**

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IN THIS ISSUE</strong></td>
<td>Highlighted research articles</td>
<td>621</td>
</tr>
<tr>
<td><strong>NEWS IN BRIEF</strong></td>
<td>Important news stories affecting the community</td>
<td>624</td>
</tr>
<tr>
<td><strong>NEWS IN DEPTH</strong></td>
<td>Q&amp;A: Brian Kennedy on Aging and Cancer</td>
<td>627</td>
</tr>
<tr>
<td><strong>RESEARCH WATCH</strong></td>
<td>New Nanomedicines May Better Target Tumors</td>
<td>628</td>
</tr>
<tr>
<td><strong>ONLINE</strong></td>
<td>Selected highlights of recent articles of exceptional significance from the cancer literature</td>
<td>629</td>
</tr>
</tbody>
</table>

**VIEWS**

- **In The Spotlight**
  - Second-Generation ALK Inhibitors: Filling the Non-MET Gap | 634
  - See article, p. 662
  - Soil Amendments That Slow Cancer Growth | 637
  - See article, p. 716
  - VEGFA Genomic Amplification Tailors Treatment of HCCs with Sorafenib | 640
  - See article, p. 730
  - EML4–ALK Fusions: Propelling Cancer but Creating Exploitable Chaperone Dependence | 642
  - P. Workman and R. van Montfort

**In Focus**

- Surviving Metabolic Stress: Of Mice (Squirrels) and Men | 646
  - W.N. Hait, M. Versele, and J.-M. Yang

**REVIEW**

- Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA | 650
  - D.A. Haber and V.E. Velculescu

**RESEARCH ARTICLES**

- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer | 662
  - See commentary, p. 634

- Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation | 674
  - See article, p. 662

- Inflammation-Induced NFATc1–STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by Kras<sup>6120</sup> | 688
  - See article, p. 716

- EML4–ALK Fusions: Propelling Cancer but Creating Exploitable Chaperone Dependence | 642
  - P. Workman and R. van Montfort

- Surviving Metabolic Stress: Of Mice (Squirrels) and Men | 646
  - W.N. Hait, M. Versele, and J.-M. Yang

**IN THIS ISSUE**

- **NEWS IN BRIEF**
  - Important news stories affecting the community

- **NEWS IN DEPTH**
  - Q&A: Brian Kennedy on Aging and Cancer

- **RESEARCH WATCH**
  - Selected highlights of recent articles of exceptional significance from the cancer literature

- **ONLINE**
  - For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.
Friboulet and colleagues report that ceritinib, a next-generation ALK inhibitor that is more selective and potent than crizotinib, is active in preclinical models of both crizotinib-naïve and crizotinib-resistant non-small cell lung cancer (NSCLC). Ceritinib retained activity against the most common crizotinib-resistant ALK mutants, although some secondary ALK mutations did confer resistance to both crizotinib and ceritinib. Structural analyses provided a mechanistic basis for these findings, as the most common secondary ALK mutations that inhibit binding of crizotinib are not predicted to impair ceritinib binding, but other mutations, which the authors have identified in patients with acquired resistance to ceritinib, are predicted to reduce ceritinib binding through steric hindrance or conformational changes of the ALK catalytic domain. For details, please see the article by Friboulet and colleagues on page 662.

**Epithelial-to-Mesenchymal Transition Activates PERK-eIF2α and Sensitizes Cells to Endoplasmic Reticulum Stress** ................. 702


Précis: Elevated ECM synthesis and secretion activates the PERK arm of the UPR and renders cells that have undergone EMT vulnerable to ER stress-inducing agents.

**p38MAPK Plays a Crucial Role in Stromal-Mediated Tumorigenesis** .... 716


Précis: The secretory phenotype of cancer-associated fibroblasts that promotes tumor growth is post-transcriptionally controlled by p38MAPK.

See commentary, p. 637

AC icon indicates Author Choice

For more information please visit http://www.aacjournals.org